Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001239790 | SCV001412689 | pathogenic | Argininosuccinate lyase deficiency | 2024-10-12 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 156 of the ASL protein (p.Pro156Leu). This variant is present in population databases (rs769017508, gnomAD 0.006%). This missense change has been observed in individual(s) with argininosuccinate lyase deficiency (PMID: 29773863, 31030429). ClinVar contains an entry for this variant (Variation ID: 198384). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt ASL protein function with a positive predictive value of 95%. This variant disrupts the p.Pro156 amino acid residue in ASL. Other variant(s) that disrupt this residue have been observed in individuals with ASL-related conditions (PMID: 24166829), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV001239790 | SCV004200589 | pathogenic | Argininosuccinate lyase deficiency | 2024-03-27 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000179702 | SCV000231993 | uncertain significance | not provided | 2017-10-27 | flagged submission | clinical testing | |
Natera, |
RCV001239790 | SCV002076006 | likely pathogenic | Argininosuccinate lyase deficiency | 2021-02-16 | no assertion criteria provided | clinical testing |